How to Safeguard Your Kidneys During Chemotherapy: Proven Strategies and Research Insights

Medications and additional intravenous (IV) fluids are routinely used to reduce the risk of chemotherapy‑induced kidney injury.

Each year more than one million Americans undergo chemotherapy or radiation for cancer. Many of the drugs used are eliminated by the kidneys, which can place the organs at risk for damage.

To protect kidney function, oncologists monitor renal health before, during, and after treatment. This may involve prescribing protective agents, increasing IV fluid volumes, or temporarily adjusting the chemotherapy regimen.

Typical pre‑treatment assessments include:

• Measuring fluid and electrolyte levels to gauge baseline kidney performance.
• Administering extra IV fluids to flush chemotherapy metabolites.
• Prescribing nephroprotective drugs such as amifostine.
• Addressing co‑existing medical conditions that could worsen renal stress.
• Considering dose reduction or dialysis if kidney function is already compromised.

Nephrotoxicity describes a decline in kidney function caused by toxic chemicals or medications. The chemotherapy agents most frequently linked to nephrotoxicity are:

• Methotrexate
• Semustine
• Streptozocin
• Mithramycin
• Cisplatin

These nephrotoxins can trigger cyst formation, inflammation, and structural damage, potentially leading to chronic kidney disease or renal failure. In many patients, kidney function improves once the offending drugs are discontinued and the organs are no longer exposed to toxic metabolites.

Factors that influence recovery include:

• Pre‑existing kidney disease.
• Duration and intensity of chemotherapy.
• Specific drugs used.
• Concurrent treatments such as radiation therapy.

Close monitoring enables clinicians to lower drug doses or pause treatment before irreversible injury occurs.

A 2019 analysis of 163,071 patients receiving chemotherapy or targeted therapy reported acute kidney injury (AKI) in 9.3 % of cases. Injuries were twice as likely within the first 90 days after treatment, with the highest rates observed in multiple myeloma, bladder cancer, and leukemia.

Advanced cancer stage, baseline kidney disease, and diabetes were identified as additional risk factors.

Research in pediatric oncology shows that 56 % of children experience kidney or urinary‑tract problems during or shortly after therapy. Although severe kidney disease remains uncommon in long‑term survivors, its prevalence is still higher than in healthy siblings.

If chemotherapy damages the kidneys, physicians may recommend lifestyle modifications, medication adjustments, dose reductions, or dialysis.

Key lifestyle measures include:

• Avoiding alcohol and tobacco.
• Following a low‑sodium, low‑potassium, and low‑phosphorus diet read more here.
• Engaging in regular physical activity and achieving a healthy weight.

While no drug can cure kidney disease, diuretics can help remove excess fluid and waste. In cases where the kidneys cannot adequately filter blood, dialysis becomes necessary.

In summary, protecting renal health during chemotherapy involves proactive testing, generous IV hydration, nephroprotective medications, vigilant monitoring, and, when needed, treatment adjustments or dialysis.